SUMMARY In an open study 120 consecutively admitted premature babies of 32 weeks' gestation or less, were randomised to receive weekly intramuscular injections of human normal immunoglobulin (50 mg/kg). There was no significant difference between the number of babies in the treated and untreated groups who had at least one episode of infection, but the total number of infective episodes was substantially less in the treated group (n=22) 
Premature babies have low serum immunoglobulin concentrations at birth and do not start producing appreciable amounts of endogenous immunoglobulin until they are at least 15 weeks old.' Premature infants of 32 weeks' gestation or less are particularly compromised, their IgG concentrations being liable to fall to 2-0 g/l or less as early as six weeks after birth. A baby born at term at a similar postnatal age has a serum IgG concentration of about 6-0 g/1.2 Despite intensive treatment with antibiotics infection remains an important cause of mortality and morbidity in premature babies. This study aimed to determine whether treatment with intramuscular human normal immunoglobulin could decrease either the morbidity or mortality or both, associated with infection in premature infants.
Patients and methods
One hundred and twenty preterm babies of 32 weeks' gestation or less, who were consecutively admitted to a regional neonatal unit, were randomised to receive human normal immunoglobulin 50 mg/kg intramuscularly weekly (n=59) or remained untreated (n=61) (table 1). (It would have been unethical to have used a double blind protocol in which the control group received weekly placebo intramuscular injections.) The immunoglobulin, which was prepared by the Blood Products Laboratory, Elstree, and issued by the Central Public Health Laboratory, London, was injected into the lateral aspect of the upper thigh. Blood was sampled for IgG within the first 48 hours of life, before transfusion of blood or any blood products, and then every two weeks until discharge on the first 100 babies. Serum IgG concentrations were measured by a standard centrifugal fast analyser (Encore, Baker Instruments).
All clinically suspected episodes of infection and the results of allied investigations (full blood count, The proportions of treated and untreated babies who had at least one infective episode in category B
Results
Twelve babies who died within two days of birth and one baby who died when 4 days old (seven in the treatment group and six in the control group) from complications of extreme prematurity (severe intraventricular haemorrhage, severe perinatal asphyxia, pulmonary haemorrhage, pulmonary interstitial emphysema, or pneumothoraces) were not included in the final analysis.
The mean gestational age of the remaining 107 babies was 29-3 weeks (range 24-32), and mean birth weight 1220 g (range 600-2200). Both groups were comparable for gestational age, birth weight, sex, and length of follow up. There were no significant differences between the groups in the incidence of intraventricular haemorrhage, respiratory distress syndrome, maximum inspiratory pressure, maximum inspired oxygen received, number of days of oxygen supplement given, total time of intermittent positive pressure ventilation, number of days of total parenteral nutrition, time to starting After the identification of wheat flour as the cause of coeliac disease by Dicke in Holland in 1950 the search began for the noxious factor in the flour. By 1952-53 it had been confirmed that gluten, the protein fraction of wheat and rye flour, was the cause of the malabsorption. Wheat and rye gluten differ from other cereal proteins in containing more glutamic acid and proline, which can form a type of gel enabling them to be used in breadmaking. The group from Melbourne, noting that the peptide pattern in the gluten molecule is probably associated with the gel property, set out to test the hypothesis that the particular peptide structure of wheat and rye gluten, together with a difference in the enzyme pattern of the patient with coeliac disease, might be responsible for the development of symptoms. Various fractions of gluten were tested. The phospholipid fraction when extracted and fed to a patient with coeliac disease failed to produce an increase in fat excretion. A tryptic digest of gluten to peptides caused a recurrence of steatorrhoea, while neither an amino acid digest or glutamic acid alone had this effect. Blood glutamine concentrations tested two hours after a dose of gluten were found to be three times higher in patients with coeliac disease than in controls, and Weijers and Van de Kamer had reported similar results from feeding gliadin (the 70% alcohol soluble fraction of gluten).
It was concluded that glutamine itself was not toxic to the patient with coeliac disease but that the toxic fraction was a peptide containing glutamine, and a deficiency of a specific mucosal peptidase that might deaminate the peptide was postulated.
Comment. In the 30 years since the publication of this paper the development of immunology has radically altered our understanding of many disorders. The evidence now points strongly to coeliac disease reflecting an intestinal immune response to gliadin or to peptides from gliadin. The technique of peroral intestinal biopsy was developed by Shiner in 1956, and the characteristic enteropathy of coeliac disease has been shown to be a T cell mediated immune reaction. It has been proposed that lymphocines, secreted by activated T cells, are the mechanism for T cell mediated mucosal damage. Other evidence of immunological abnormality is the fact that subjects with isolated IgA deficiency are particularly prone to develop coeliac disease. We are far from a complete understanding of a complex process and, as yet, we do not have any routine laboratory tests for the measurement of intestinal immune reactions. 
